Skip to main content

Sarcopenia and Physical fRailty IN older people: multi-componenT Treatment strategies

Objective


The current healthcare systems are built around the traditional paradigm of patients suffering from a single acute illness. They are therefore largely unprepared to face the increasing demands for health services arising from the expansion of an older population with specific medical needs related to multiple chronic disorders. As a consequence, the medical conditions of a large and growing segment of the older European population are not efficiently managed by the available healthcare services. Among these conditions, the geriatric syndrome of frailty has emerged as a significant public health priority. It is defined as a multidimensional condition characterised by decreased reserve and diminished resistance to stressors. Such extreme vulnerability exposes the older individual to an increased risk of morbidity, disability, inappropriate healthcare use, institutionalization, poor quality of life, and death. Early detection and prevention of frailty are thus crucial to impede its progression and the development of its detrimental clinical consequences, while ensuring sustainability of healthcare systems of the Member States. Unfortunately, to date, no healthcare programs or pharmacological treatments are available for frail older people. This is largely due to the lack of a precise, universal definition of frailty, linked in turn to the multidimensional nature of the condition. Eventually, the existing gaps in knowledge are reflected by the absence of effective interventions. Such a barrier may be overcome by developing and validating a robust conceptual framework to achieve a practical operationalisation of frailty. This should precisely define its pathophysiological and clinical foundations, to assist in the design and implementation of specific interventions aimed at restoring robustness and delaying the onset of adverse outcomes. The present “Sarcopenia and Physical fRailty IN older people: multi-componenT Treatment strategies” (SPRINTT) project is specifically designed to overcome the existing barriers for an efficient public health intervention against frailty, and promote the implementation of successful aging strategies across Europe.
To reach such an ambitious goal, the actions of the SPRINTT Consortium are directed towards the achievement of a consensus among academia, regulators, industry (pharmaceutical and medical devices), and patients’ representatives over
(1) clear operationalisation of the presently vague concept of frailty;
(2) identification of a target population with unmet medical needs;
(3) evaluation and validation of methodologies for implementing preventive and therapeutic strategies among frail elders at risk of disability in the European Union;
(4) definition of an experimental setting as a template for regulatory purposes and pharmaceutical investigations;
(5) identification of biomarkers and health technology solutions to be implemented into clinical practice.
Thus, the project is expected to pursue all the research deliverables described in nine work-packages.
The SPRINTT project proposes a novel operationalisation of physical frailty recognising sarcopenia as its central biological substrate. This approach is based on the fact that the physical frailty phenotype overlaps substantially with sarcopenia. Indeed, many of the adverse outcomes of frailty are probably mediated by sarcopenia, which may therefore represent both the biological substrate for the development of physical frailty and the pathway through which the negative health outcomes of frailty ensue. Although physical frailty encompasses only a part of the frailty spectrum, the identification of a definite biological basis (i.e., skeletal muscle decline and loss of mobility function) opens new venues for the development of interventions to slow or reverse the progression of this condition. It is noteworthy that all of the components characterising the Physical Frailty and Sarcopenia (PF&S) model are measurable and qua

Call for proposal

IMI-JU-09-2013
See other projects for this call

Funding Scheme

JTI-CP-IMI - Joint Technology Initiatives - Collaborative Project (IMI)

Coordinator

SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT
Address
Pierre Brossolette 1
91380 Chilly Mazarin
France
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Principal investigator
Susanna Del Signore (Dr)
Administrative Contact
Philippe BORDES (-)

Participants (25)

UNIVERSITA CATTOLICA DEL SACRO CUORE
Italy
EU contribution
€ 4 331 715
Address
Largo Gemelli 1
20123 Milano
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Luca Mariotti (PMP)
CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE
France
EU contribution
€ 2 247 516
Address
Rue Viguerie 2 Hotel Dieu Saint Jacques
31052 Toulouse Cedex 3
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Sophie Mourgues (Dr)
UNIVERZITA KARLOVA
Czechia
EU contribution
€ 757 192
Address
Ovocny Trh 560/5
116 36 Praha 1
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Kristyna Matejkova (Mrs.)
ROESSINGH RESEARCH AND DEVELOPMENT BV
Netherlands
EU contribution
€ 200 046
Address
Roessinghsbleekweg 33
7522 AH Enschede
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Miriam Vollenbroek-Hutten (Prof. dr.)
HELSINGIN YLIOPISTO
Finland
EU contribution
€ 1 113 795
Address
Yliopistonkatu 3
00014 Helsingin Yliopisto
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Tiina Berg (Ms)
CARETEK SRL
Italy
EU contribution
€ 2 450 000
Address
Via Pio Vii 127
10127 Torino
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Gianluca Zia (Ing.)
EU-Open S.R.L.
Italy
EU contribution
€ 501 841
Address
Via Marconi
37040 Veronella (Vr)
Administrative Contact
barbara cibin (doctor)
SERVICIO MADRILENO DE SALUD
Spain
EU contribution
€ 2 146 723
Address
Plaza Carlos Trias Bertran 7
28020 Madrid
Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
Administrative Contact
BELEN RIQUELME GARCIA (MS.)
UNIVERSITE PARIS DESCARTES
France
EU contribution
€ 368 980
Address
Rue De L Ecole De Medecine 12
75270 Paris Cedex 06
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Rosaly DATCHI (Ms)
UNIVERSITA DEGLI STUDI DI FIRENZE
Italy
EU contribution
€ 253 290
Address
Piazza San Marco 4
50121 Florence
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Marigrazia Catania (Ms.)
FRIEDRICH-ALEXANDER-UNIVERSITAET ERLANGEN-NUERNBERG
Germany
EU contribution
€ 1 417 794
Address
Schlossplatz 4
91054 Erlangen
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Franziska Müller (Ms)
UNIWERSYTET JAGIELLONSKI
Poland
EU contribution
€ 867 536
Address
Ul. Golebia 24
31007 Krakow
Activity type
Other
Administrative Contact
Katarzyna Gubernat (Ms)
ISTITUTO NAZIONALE DI RIPOSO E CURA PER ANZIANI INRCA
Italy
EU contribution
€ 1 670 125
Address
Via Santa Margherita 5
60124 Ancona
Activity type
Research Organisations
Administrative Contact
Maria Grazia Palermi (Doctor)
GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD.
United Kingdom
Address
Great West Road 980
TW89GS Brentford
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Sally Miles (-)
INSTITUT DE RECHERCHES INTERNATIONALES SERVIER IRIS
France
Address
Rue Carnot 50
92284 Courbevoie
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Marie DUVICQ (Ms)
NOVARTIS PHARMA AG
Switzerland
Address
Lichtstrasse 35
4056 Basel
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Barbara Stolz (Dr.)
Eli Lilly and Company Limited

Participation ended

United Kingdom
Address
Lilly House, Priestley Road
RG24 9NL Basingstoke
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Birgit Steckel-Hamann (Dr)
UNIVERSITAETSMEDIZIN GOETTINGEN - GEORG-AUGUST-UNIVERSITAET GOETTINGEN - STIFTUNG OEFFENTLICHEN RECHTS
Germany
EU contribution
€ 1 513 500
Address
Robert-koch-strasse 40
37075 Goettingen
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Christiane Hennecke (M.A.)
NICHE SCIENCE & TECHNOLOGY LTD

Participation ended

United Kingdom
Address
Wolsey Drive 96
KT2 5DW Kingston Upon Thames
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Tim Hardman (Dr)
DIABETES FRAIL LIMITED
United Kingdom
EU contribution
€ 1 388 298
Address
Oakmoore Court 11 C Kingswood Road Hapmton Lovett
WR9 0QH Droitwitch
Activity type
Research Organisations
Administrative Contact
Caroline Sinclair (Mrs)
UNIVERSITEIT MAASTRICHT
Netherlands
EU contribution
€ 704 088
Address
Minderbroedersberg 4-6
6200 MD Maastricht
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Pascal Stevens (MSc, RC)
ASTON UNIVERSITY
United Kingdom
EU contribution
€ 715 300
Address
Aston Triangle
B4 7ET Birmingham
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Kevin O'Reilly (Mr)
UNIVERSITA DEGLI STUDI DI PARMA
Italy
EU contribution
€ 650 000
Address
Via Universita 12
43100 Parma
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Pietro Schianchi (Dottore)
HASKOLI ISLANDS
Iceland
EU contribution
€ 349 650
Address
Saemundargotu 2
101 Reykjavik
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Alfons Ramel (PhD)
MEDIZINISCHE UNIVERSITAT GRAZ
Austria
EU contribution
€ 352 050
Address
Auenbruggerplatz 2
8036 Graz
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Kristina Kofler (Dr.)